Evidence map›Paper›PMID 38089653›Full record

ReviewACS materials Au2023

3D Printing for Cancer Diagnosis: What Unique Advantages Are Gained?

Yu Zhang

Open access · goldAbstract readReview
In one paragraph

Review in ACS materials Au, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Yu ZhangDivision of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, Texas 78705, United States.ORCID https://orcid.org/0000-0002-8925-2284
University of Mississippi · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is a complex disease with global significance, necessitating continuous advancements in diagnostics and treatment. 3D printing technology has emerged as a revolutionary tool in cancer diagnostics, offering immense potential in detection and monitoring. Traditional diagnostic methods have limitations in providing molecular and genetic tumor information that is crucial for personalized treatment decisions. Biomarkers have become invaluable in cancer diagnostics, but their detection often requires specialized facilities and resources. 3D printing technology enables the fabrication of customized sensor arrays, enhancing the detection of multiple biomarkers specific to different types of cancer. These 3D-printed arrays offer improved sensitivity, allowing the detection of low levels of biomarkers, even in complex samples. Moreover, their specificity can be fine-tuned, reducing false-positive and false-negative results. The streamlined and cost-effective fabrication process of 3D printing makes these sensor arrays accessible, potentially improving cancer diagnostics on a global scale. By harnessing 3D printing, researchers and clinicians can enhance early detection, monitor treatment response, and improve patient outcomes. The integration of 3D printing in cancer diagnostics holds significant promise for the future of personalized cancer care.

Identifiers

PMID38089653
PMCPMC10636786
OpenAlexW4386219687

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.